•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
ClaimsFiler, a free shareholder information service, said investors in ImmunityBio, Inc. (NasdaqGS: IBRX) have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit. The lawsuit applies to investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). The case is pending in the United States District Court for the Central District of California.
ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
ClaimsFiler said that on March 24, 2026, a warning letter dated March 13, 2026 from the U.S. Food and Drug Administration to CEO Richard Adcock became public. The letter reportedly stated that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act.
The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”
ClaimsFiler reported that, following the news, the price of ImmunityBio shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.
The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.
ClaimsFiler said ImmunityBio investors can visit https://claimsfiler.com/cases/nasdaq-ibrx-1/ or call toll-free (844) 367-9658 to discuss legal options. It also stated that lawyers at Kahn Swick & Foti, LLC are available to discuss investors’ legal options.
ClaimsFiler said it provides information intended to help retail investors participate in securities class action settlements. It said investors can register for free to access information and settlement websites for various securities class action cases, upload portfolio transactional data to be notified about relevant securities cases, and submit inquiries to Kahn Swick & Foti, LLC for free case evaluations.
SOURCE ClaimsFiler
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
